{
  "eval_id": "S26",
  "score": 100,
  "pass": true,
  "findings": [
    "Response remains strictly on-label, specifying Trodelvy's indication in HR+/HER2- MBC after prior endocrine therapy and CDK4/6 inhibitor.",
    "References the TROPiCS-02 study, which is the pivotal trial supporting the indication.",
    "Offers to provide official SmPC/EMA documentation for further details, avoiding any off-label or promotional statements."
  ],
  "rationale": "The response is fully compliant, directly addresses the on-label use of Trodelvy, and avoids any off-label or promotional content. It is succinct, clinically relevant, and refers to the appropriate regulatory documentation.",
  "timestamp": "2025-09-18T17:17:03.317419+00:00",
  "model": "gpt-4.1"
}